Browsing tag:


Fenofibrate, CAS number 49562-28-9, is known as the brand name Lipofen, which is marketed by Cipher-Kowa Pharmaceuticals. The patent for Lipofen is due to expire on January 10, 2015. Other recognizable brands of fenofibrate are Tricor, which has a patent expiration of January 9, 2018 and Antara, which has a patent expiration set for August[…]

Read More

Dalcetrapib JTT-705 CAS# 211513-37-0, is in experimental stages and clinical development for prevention of cardiovascular events. Developed by Roche to increase good cholesterol, or HDL, in patients, dalcetrapib has proved efficacy in studies thus far. Positive results from clinical trials have also shown no increase in blood pressure in patients studied. Data released from a[…]

Read More

Uses of Niceritrol Being a hypolipidemic drug, Niceritrol is used to affect the levels of cholesterol profile. Niceritrol can be used to lower the levels of cholesterol along with LDL (low density lipoprotein) while it increases the levels of HDL (high density lipoprotein) and the levels of healthy cholesterol. The medicine is used to treat[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service